Xenbase Image ID: 77493

Figure 7. GO term analysis of fus-affected genes. (A) Intron-retained genes in fus morphants are enriched for developmental regulators. Heat map showing GO slim terms annotated to intron-retained genes in fus morphants and expressed genes at stage 10 and stage 12. GO slim categories that are significantly enriched in fus-affected genes are indicated in red, and categories that are depleted are in blue. GO slim categories that contain terms associated with embryo development, morphogenesis, and differentiation (anatomical structure morphogenesis, cell differentiation, and embryonic development) are enriched in fus-affected genes. Also enriched are terms associated with transcription (nucleic acid binding and transcription factor activity) and signal transduction (signal transducer activity). (Inset) Values are expressed as a fraction of genes that are assigned the GO slim term, with rarely represented terms in yellow and more common terms in red. (***) P < 0.001; (**) P < 0.01 at both stage 10 and stage 12. (*) P < 0.05 at stage 12 only. Only GO slim terms from levels 3 and 4 in the categories “molecular function” and “biological process,” respectively, are shown. (B) All major developmental signaling pathways are affected in fus morphants. Bar graph showing the representation of GO signal categories in fus-affected genes expressed as fold change compared with expressed genes. The major developmental pathways regulated by either activin, adhesion, bone morphogenetic protein (bmp), fgf, hedgehog (hh), MAP kinase (mapk), notch, retinoic acid (ra), smad, tgf-β (tgfb), and wnts are enriched at stages 10 and 12. In contrast, GO terms associated with transfer RNA (tRNA), telomere, and intracellular vesicles (vesicle) are depleted in fus-affected genes. The red line indicates no change. Image published in: Dichmann DS and Harland RM (2012) Copyright © 2012. Image reproduced on with permission of the Publisher, Cold Spring Harbor Laboratory Press. This is an Open Access article. Larger Image Printer Friendly View

Return to previous page